SHANGHAI, August 20, 2021 -- BioNova Pharmaceuticals (Shanghai) Ltd. (BioNova) and Insilico Medicine (Insilico), today announced entry into a collaboration agreement to jointly discover small molecule inhibitors by targeting oncogenic pathways, which are believed to be dominant drivers of specific hematologic malignancies.